These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18602742)

  • 21. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
    Van der Kwast TH; Bolla M; Van Poppel H; Van Cangh P; Vekemans K; Da Pozzo L; Bosset JF; Kurth KH; Schröder FH; Collette L;
    J Clin Oncol; 2007 Sep; 25(27):4178-86. PubMed ID: 17878474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer.
    Van Poppel H; Joniau S
    Eur Urol; 2008 Feb; 53(2):253-9. PubMed ID: 17949893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-radical prostatectomy management options for the positive surgical margin: argument for adjuvant radiotherapy.
    Chin JL
    Urol Oncol; 2009; 27(1):87-8. PubMed ID: 19111805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
    Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
    JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer.
    Rossi CJ; Joe Hsu IC; Abdel-Wahab M; Arterbery VE; Ciezki JP; Frank SJ; Hahn NM; Moran BJ; Rosenthal SA; Merrick G
    Am J Clin Oncol; 2011 Feb; 34(1):92-8. PubMed ID: 21270599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Postoperative radiotherapy of prostate cancer].
    Richaud P; Sargos P; Henriques de Figueiredo B; Latorzeff I; Mongiat-Artus P; Houédé N; Salomon L; Wallerand H
    Cancer Radiother; 2010 Oct; 14(6-7):500-3. PubMed ID: 20810300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy.
    Loeb S; Roehl KA; Viprakasit DP; Catalona WJ
    Eur Urol; 2008 Jul; 54(1):88-94. PubMed ID: 18400368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.
    Moinpour CM; Hayden KA; Unger JM; Thompson IM; Redman MW; Canby-Hagino ED; Higgins BA; Sullivan JW; Lemmon D; Breslin S; Crawford ED; Southwest Oncology Group
    J Clin Oncol; 2008 Jan; 26(1):112-20. PubMed ID: 18165645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
    Peeters ST; Heemsbergen WD; Koper PC; van Putten WL; Slot A; Dielwart MF; Bonfrer JM; Incrocci L; Lebesque JV
    J Clin Oncol; 2006 May; 24(13):1990-6. PubMed ID: 16648499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.
    Al-Mamgani A; van Putten WL; Heemsbergen WD; van Leenders GJ; Slot A; Dielwart MF; Incrocci L; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):980-8. PubMed ID: 18495377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Salvage radiotherapy in rising PSA after radical prostatectomy].
    Carrie C; Pommier P
    Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.
    Kuban DA; Tucker SL; Dong L; Starkschall G; Huang EH; Cheung MR; Lee AK; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):67-74. PubMed ID: 17765406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?
    King CR; Kapp DS
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):346-50. PubMed ID: 18234451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
    Raldow A; Hamstra DA; Kim SN; Yu JB
    Cancer Treat Rev; 2011 Apr; 37(2):89-96. PubMed ID: 20667660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter.
    Zhang Q; Fu S; Liu T; Peng L; Huang G; Lu JJ
    Urol Oncol; 2009; 27(1):14-20. PubMed ID: 18367127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
    Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.